vismodegib

And Curis immediately spent a big chunk of that to in-license an experimental cancer therapy from its colleagues at Genentech, flipping the usual order of deal-making as the little biotech paid the giant Roche subsidiary a small upfront to gain development rights.

A skin cancer drug developed by Roche/Genentech appears to beat back breast cancer cells resistant to tamoxifen, a standard course of treatment, researchers from Ohio have discovered.

When Roche tried to gain an approval to use T-DM1 against breast cancer based on mid-stage results from a single-arm study, the FDA sent its regulatory team packing--refusing to even review the

Armed with positive data from a pivotal Phase II trial, Lexington, MA-based Curis is waiting for its partner Roche to begin its long-awaited pitch to gain FDA approval for a new treatment for